Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | PYGM | P11217 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770116 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL2577234 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL10341279 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL11209925 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL10341278 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL10341280 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1THRBMDM2 | |
| Hydrochloric Acid SCHEMBL10888552 | 0.89 | LMNA (0.49) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL2582673 | 0.89 | LMNA (0.49) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL6716527 | 0.89 | PDE2A (0.55) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL6716522 | 0.89 | PDE2A (0.55) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| EP-4023233-A2 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220088097-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2022-03-24 | — | — | US | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| EP-3518947-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064134-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2018-04-05 | — | — | WO | claimed |
| US-20180085411-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2018-03-29 | — | — | US | claimed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | claimed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| EP-0653439-B1 | Stabilized oligonucleotids and the use thereof | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | claimed |
| US-6020483-A | Nucleoside modifications by palladium catalyzed methods | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885MTOR 131/4885ALDH1A1 4371/4885 |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885MTOR 131/4885ALDH1A1 4371/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885MTOR 531/4885ALDH1A1 2112/4885 |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.